Physician profile
Thomas D Bryan
NPI 1073990511
$5,119.13
in general payments reported to CMS, 2019-2025
43 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $240 · 2021: $103 · 2022: $1,077 · 2023: $1,016 · 2024: $1,045 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.51 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $373.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $361.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $337.41 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $293.21 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $273.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.99 | 2021-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $228.02 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $217.00 | 2019-2025 | Otezla, Repatha, Evenity |
| Dexcom, INC. | $207.86 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $202.93 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $197.93 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.56 | 2020-2023 | Trintellix |
| Astellas Pharma US INC | $125.84 | 2019-2025 | Veozah |
| Dynavax Technologies Corporation | $103.21 | 2022-2025 | Heplisav-B |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.